Storia in 4 fonti

LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference® (AAIC®) 2026

Raccontata da

healio.com

markets.businessinsider.com

morningstar.com

economictimes.indiatimes.com

Confronto fonti

4 prospettive sulla stessa storia

AI · summaries

morningstar.comStai leggendo1 mese fa

LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in…

originale

Timeline cronologica

domenica 12 luglio 2026·healio.com
Subcutaneous, intravenous outcomes with lecanemab comparable in Alzheimer’s disease
Outcomes following subcutaneous and intravenous treatment with lecanemab for Alzheimer’s disease were comparable, according to a group of abstracts presented at the Alzheimer’s…
domenica 12 luglio 2026·markets.businessinsider.com
Biogen, Eisai announce new data on efficacy, safety of LEQEMBI SC-AI
Eisai (ESAIY) and Biogen (BIIB) announced that new data presented at the Alzheimer’s Association International Conference, AAIC, 2026 in London ...

LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference® (AAIC®) 2026

Confronto fonti

LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in…

Timeline cronologica

Subcutaneous, intravenous outcomes with lecanemab comparable in Alzheimer’s disease

Biogen, Eisai announce new data on efficacy, safety of LEQEMBI SC-AI

Biogen, Eisai announce new data on efficacy, safety of LEQEMBI SC-AI

FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug

Subcutaneous, intravenous outcomes with lecanemab comparable in Alzheimer’s disease

LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease…

FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease

ADDF Statement: FDA Approval of Subcutaneous Starting Dose for Leqembi Advances Alzheimer's Care Toward Combination Therapy Future

FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's disease

FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug

More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world…